Discontinuation report IMFINZI
| Report ID | 257688 |
| Drug Identification Number | 02468816 |
| Brand name | IMFINZI |
| Common or Proper name | Common or Proper name |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | DURVALUMAB |
| Strength(s) | 50MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | Packaging size |
| ATC code | L01XC |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-03-03 |
| Actual discontinuation date | 2023-02-04 |
| Remaining supply date | 2024-01-17 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-11-19 | French | Compare |
| v3 | 2025-11-19 | English | Compare |
| v2 | 2025-11-12 | French | Compare |
| v1 | 2025-11-12 | English | Compare |
Showing 1 to 4 of 4